Japan SJS/TEN Treatment Market

Japan SJS/TEN Treatment Market Summary:

According to Transpire Insights, a detailed research report on the market reflects that the Japan SJS/TEN Treatment Market accounted for approximately USD 28.4 million in 2025, is expected to reach USD 29.3 million in 2026, and is estimated to reach USD 36.6 million by 2033, expanding at a CAGR of 3.23% during 2026–2033, making it a steadily growing market driven by increasing awareness of SJS/TEN treatment, advancements in therapeutic approaches, improved supportive care, early diagnosis and intervention, enhanced treatment capabilities, and ongoing developments in the management of severe drug-induced skin reactions in Japan.

Market Snapshot

• Market Value (2025): USD 28.4 Million.
• Expected Market Value (2026): USD 29.3 Million.
• Estimated Market Value (2033): USD 36.6 Million.
• Forecast CAGR (2026–2033): 3.23%

Introduction

The Japan SJS/TEN Treatment Market is a niche healthcare environment focused on the diagnosis, treatment and management of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), serious adverse cutaneous reactions that require immediate and coordinated medical attention. The market includes systemic corticosteroids, immunomodulatory therapies, intravenous immunoglobulin, wound care, pain management, critical care services and speciality ophthalmic treatments. Japan has developed specific clinical approaches, emphasising early therapeutic intervention, multidisciplinary management and prevention of long-term complications, especially severe ocular damage. Advances in regenerative ophthalmology, cultivated oral mucosal epithelial transplantation, specialised contact lens technologies, and emerging biologic therapies are also bolstering the treatment landscape. Growing clinical expertise, better supportive-care infrastructure and ongoing therapeutic innovation are driving the Japan SJS/TEN treatment market.

Key Market Highlights: -

• By Treatment Type, the Systemic Corticosteroids dominated the market and holds approximately 64% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Disease, the Stevens - Johnson syndrome dominated the market and holds approximately 61% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Drug/Therapy, the Bariatric Surgery Devices Manufacturers segment dominated the market and holds approximately 65% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• Japan’s SJS/TEN therapeutic landscape is strengthened by improved pharmacovigilance, specific clinical guidelines, genetic risk assessment and regulatory efforts to improve earlier diagnosis, safer use of medications and faster development of novel therapeutics.

How is Technology Driving Growth in the Japan SJS/TEN Treatment Market?

Technology is strengthening the Japan SJS/TEN Treatment Market through improved early risk identification, treatment precision, ocular recovery, and long-term patient management. Regenerative ophthalmology, including cultivated oral mucosal epithelial transplantation, is expanding the alternatives for patients with severe ocular complications. Pharmacogenomic testing identifies susceptibility to drug reactions and helps ensure safer prescribing practices. Innovative diagnostic tools, clinical databases, biobanking and multidisciplinary care networks are improving evidence generation and treatment coordination. Emerging biologic and immunomodulatory therapies are expanding treatment options for severe or refractory disease. Digital health infrastructure facilitates pharmacovigilance, clinical monitoring and continuity of specialised care.

Market Drivers

Growing demand for specialised management of severe drug-induced cutaneous reactions, particularly in ageing patients taking multiple medications, is driving the Japan SJS/TEN Treatment Market. The increasing use of antiepileptics, antibiotics, oncology therapies and other potentially causative drugs makes the need for rapid diagnosis and intensive treatment even more important. Established clinical protocols in Japan further support market development with a focus on early intervention, systemic corticosteroid therapy, intravenous immunoglobulin and comprehensive supportive care. Advances in ophthalmic management, including specific treatment for ocular complications of SJS/TEN, further expand therapeutic options. Evolving pharmacovigilance practices, multidisciplinary care and treatment innovation are all collectively bolstering the Japanese SJS/TEN treatment landscape.

Restrain

The Japan SJS/TEN Treatment Market is limited by the rarity of these severe conditions, which restricts the patient population who can be treated and the commercial incentives for extensive therapeutic development. Additional limitations to dermatology laser growth are created by the intricacy of treatment, diagnostic difficulties, lack of high-quality clinical evidence, and the nonexistence of standardised therapeutic protocols worldwide. Established systemic therapies and supportive-care approaches can also reduce opportunities for differentiated products. In addition, Japan’s strict regulatory requirements, healthcare reimbursement system, and emphasis on pharmacovigilance pose additional challenges to the introduction and commercialisation of new SJS/TEN therapies.

Analysis of Prices and Consumer Behaviour

The Japan SJS/TEN treatment market is characterized by specialized treatment approaches such as systemic corticosteroids, intravenous immunoglobulin (IVIG), supportive care and advanced ophthalmic interventions. The market is valued at USD 28.4 million in 2025, which is expected to reach USD 29.3 million in 2026 and estimated to reach USD 36.6 million by 2033, growing at a CAGR of 3.23% during the forecast period of 2026-2033. The treatment landscape is driven by timely and clinically appropriate treatment for severe SJS/TEN cases. Advanced therapies and specialized ocular care aid differentiation in treatment. The purchasing behavior of healthcare providers is strongly oriented toward the efficacy and safety of the treatment, clinical evidence and reliable availability. Another important element is the adoption of established treatment protocols and coordinated procurement practices to ensure consistent access to essential therapies and supportive-care products nationwide in Japan.

Top Companies in the Japan SJS/TEN Treatment Market

• Roche
• Sanofi
• Pfizer
• Novartis
• AbbVie
• Bristol Myers Squibb
• Johnson & Johnson
• Takeda
• Astellas Pharma
• Chugai Pharmaceutical
• Kyowa Kirin
• Ono Pharmaceutical
• Daiichi Sankyo
• Shionogi
• Otsuka Pharmaceutical

Japan SJS/TEN Treatment Market Segmentation

The Japan SJS/TEN Treatment Market share is divided into six categories: By Treatment Type, By Disease, By Drug/Therapy, By Route, By End User, and By Distribution Channel

The Systemic Corticosteroids dominated the market, accounting for nearly 64% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan SJS/TEN Treatment Market is segmented by treatment type into systemic corticosteroids, ivig, cyclosporine, immunosuppressive therapy, supportive care, wound care, infection management, and combination therapy. Among these, the Systemic Corticosteroids segment dominated the market, accounting for nearly 64% in 2025 and expected to increase at a significant CAGR during the forecast period. The Systemic Corticosteroids segment dominated the market with a share of nearly 64% in 2025 and is estimated to grow at a significant CAGR over the forecast period owing to the use of systemic corticosteroids in the clinical setting for the rapid suppression of severe inflammatory responses in the management of SJS/TEN.

The Stevens-Johnson Syndrome dominated the market, accounting for nearly 61% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The Japan SJS/TEN Treatment Market is segmented by disease into stevens-johnson syndrome, toxic epidermal necrolysis, sjs/ten overlap, drug-induced sjs, infection-associated sjs, severe cutaneous adverse reaction, recurrent sjs/ten, complicated cases. Among these, the Stevens - Johnson syndrome dominated the market, accounting for nearly 61% in 2025 and expected to increase at a significant CAGR during the forecast period. The segment of Stevens - Johnson syndrome held a considerable market share of nearly 61% in 2025 and is expected to grow at a notable CAGR during the forecast period owing to the increasing treatment needs and specialised clinical management.

The Bariatric Surgery Devices dominated the market, accounting for nearly 65% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan SJS/TEN Treatment Market is segmentedby drug/therapy into corticosteroids, ivig, cyclosporine, etanercept, antibiotics, analgesics, fluid therapy, and other immunomodulators. Among these, the Bariatric Surgery Devices dominated the market, accounting for nearly 65% in 2025 and expected to increase at a significant CAGR during the forecast period. Bariatric Surgery Devices held the largest market share of around 65% in 2025 and is expected to grow at a significant CAGR during the forecast period owing to the increasing prevalence of obesity, minimally invasive procedures and increasing adoption of advanced surgical technologies.

Future Market Trends for the Japan SJS/TEN Treatment Market: -

Early Targeted Treatment: A market trend toward early guideline-based immunomodulation is emerging. Corticosteroids and certain immunosuppressive therapies are enabling early intervention and better SJS/TEN management.

Regenerative Ocular Care With recent advances in ocular treatment including cultivated oral mucosal epithelial transplantation and contact lens technologies, long-term management of ocular complications secondary to SJS/TEN will continue to improve.

Emerging Biologic Therapies: Investigation of targeted biologics and new immunomodulators is broadening therapeutic options, possibly allowing for more individualized treatment approaches in severe or refractory SJS/TEN.

Recent Development

In January 2026: Transpire Insights draws attention to Japan’s updated SJS/TEN clinical management guidelines that improve standard treatment pathways and enable advanced therapy adoption in specialized healthcare settings.

In August 2026: Japanese Clinical Research Advances Evaluation of Etanercept for Refractory SJS/TEN, Supports Emerging Targeted Treatment Strategies, Expands Japan’s Specialized Therapeutic Landscape

In October 2025: Researchers in Japan publish a new FPR1 inhibitor candidate to progress targeted therapy research for TEN and bolster the future treatment development pipeline.

Market Segmentation

This study forecasts revenue at Japan, regional and country levels from 2020 to 2033. Transpire Insights has segmented the Japan SJS/TEN Treatment Market based on the below-mentioned segments:

Japan SJS/TEN Treatment Market, By Treatment Type

• Systemic Corticosteroids
• IVIG
• Cyclosporine
• Immunosuppressive Therapy
• Supportive Care
• Wound Care
• Infection Management
• Combination Therapy

Japan SJS/TEN Treatment Market, By Disease

• Stevens-Johnson Syndrome
• Toxic Epidermal Necrolysis
• SJS/TEN Overlap
• Drug-Induced SJS
• Infection-Associated SJS
• Severe Cutaneous Adverse Reaction
• Recurrent SJS/TEN
• Complicated Cases

Japan SJS/TEN Treatment Market, By Drug/Therapy

• Corticosteroids
• IVIG
• Cyclosporine
• Etanercept
• Antibiotics
• Analgesics
• Fluid Therapy
• Other Immunomodulators

Japan SJS/TEN Treatment Market, By Route

• Intravenous
• Oral
• Subcutaneous
• Topical
• Infusion
• Injectable
• Transdermal
• Other Routes

Japan SJS/TEN Treatment Market, By End User

• Hospitals
• Burn Centers
• Dermatology Centers
• Intensive Care Units
• Emergency Departments
• Specialty Clinics
• Academic Hospitals
• Research Institutes

Japan SJS/TEN Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Direct Hospital Procurement
• Wholesalers
• Specialty Distributors
• Government Procurement
• Other Channels